27.88

1.90% -0.54

Aktis Oncology Inc (AKTS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Aktis Oncology Inc stock is traded at $27.88, with a volume of 487.20K. It is down -1.90% in the last 24 hours and up +50.05% over the past month. Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

Previous Close:

$28.42

Open:

$27.95

24h Volume:

487.20K

Relative Volume:

1.51

Market Cap:

$1.54B

Revenue:

$29.71M

Net Income/Loss:

$-69.15M

P/E Ratio:

-54.35

EPS:

-0.513

Net Cash Flow:

$-52.28M

1W Performance:

-12.22%

1M Performance:

+50.05%

6M Performance:

+24.46%

1Y Performance:

+74,846%

1-Day Range:

$26.52

$28.64

1-Week Range:

$25.84

$32.38

52-Week Range:

$14.72

$34.19

Aktis Oncology Inc Stock (AKTS) Company Profile

Name

Aktis Oncology Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

978-237-4380

Address

17 DRYDOCK AVENUE, BOSTON, NC

Employee

Twitter

@akoustisinc

Next Earnings Date

2026-08-10

Latest SEC Filings

AKTS's Discussions on Twitter

Compare AKTS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKTS Aktis Oncology Inc	27.88	1.54B	29.71M	-69.15M	-52.28M	-0.513
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Initiated	H.C. Wainwright	Buy
Feb-03-26	Initiated	BofA Securities	Buy
Feb-03-26	Initiated	JP Morgan	Overweight
Feb-03-26	Initiated	Leerink Partners	Outperform
Feb-03-26	Initiated	TD Cowen	Buy
Jan-04-24	Downgrade	Piper Sandler	Overweight → Neutral
Sep-06-23	Downgrade	B. Riley Securities	Buy → Neutral
Jan-24-23	Initiated	B. Riley Securities	Buy
Feb-02-21	Reiterated	Craig Hallum	Buy
Jan-15-21	Reiterated	Craig Hallum	Buy
Sep-18-19	Downgrade	Northland Capital	Outperform → Market Perform
Jul-10-19	Upgrade	Northland Capital	Market Perform → Outperform
May-13-19	Reiterated	Craig Hallum	Buy
Feb-05-19	Reiterated	Craig Hallum	Buy
Feb-05-19	Downgrade	Northland Capital	Outperform → Market Perform
Dec-18-18	Initiated	Craig Hallum	Buy
Nov-30-18	Initiated	Lake Street	Buy
Jun-22-18	Initiated	Loop Capital	Buy
Feb-09-18	Initiated	Drexel Hamilton	Buy

View All

Aktis Oncology Inc Stock (AKTS) Latest News

Jul 10, 2026

Aktis oncology CMO sells $1.39m in shares By Investing.com - Investing.com South Africa

Jul 10, 2026

Aktis Oncology COO Ron-Bigger sells $1.39m in shares - Investing.com UK

Jul 10, 2026

Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com - Investing.com Australia

Jul 10, 2026

Form 4 Aktis Oncology Inc For: 10 July By Investing.com - Investing.com Nigeria

Jul 10, 2026

Aktis Oncology Insiders Sold Shares Worth Over $2.8M - TradingView

Jul 10, 2026

Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares - Stock Titan

Jul 10, 2026

Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades - Stock Titan

Jul 10, 2026

Jul 08, 2026

Form 144 AKTIS ONCOLOGY For: 8 July By Investing.com - Investing.com UK

Jul 08, 2026

[144] Aktis Oncology, Inc. SEC Filing - Stock Titan

Jul 08, 2026

Jul 07, 2026

Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com

Jul 07, 2026

34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com

Jul 07, 2026

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga

Jul 07, 2026

Jul 04, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Global BMI Index - marketscreener.com

Jun 21, 2026

Jun 17, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage; Stock RisesEarnings Deceleration Risk - dars.gov.et

Jun 17, 2026

Aktis Oncology (AKTS) Gains Strong Buy Rating from Raymond James - GuruFocus

Jun 17, 2026

Jun 16, 2026

Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ) - Seeking Alpha

Jun 16, 2026

AKTS Initiates Coverage On by Raymond James -- Rating Set to Str - GuruFocus

Jun 16, 2026

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga

Jun 16, 2026

Jun 15, 2026

Raymond James initiates Aktis Oncology stock coverage with buy rating By Investing.com - Investing.com Canada

Jun 15, 2026

Jun 13, 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - AOL.com

Jun 13, 2026

Aktis Oncology (AKTS) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Jun 13, 2026

Jun 12, 2026